Upstate Active Clinical Trials
Study Title:
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (CHARM)What is the purpose of the study? (in Layman's terms, please describe the study)
To determine if BIIB093 improves functional outcome when compared with placebo in participants with Large Hemispheric Infarction (LHI)Upstate Institutional Review Board (IRB) Number:
1243116Study/Protocol ID:
252LH301Study Phase:
Phase 3Patient Age Group:
AdultsPrincipal Investigator:
Julius Gene S LatorreWhat is involved if I participate?
- How long is the study?
12 months - Is transportation provided or reimbursed?
Yes - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
ECG, neuroimaging, blood tests, NIHSS, mRS
Where will the study take place?
Upstate HospitalClinicalTrials.Gov ID:
NCT02864953For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Lena F Deb
Phone: 315-464-9756
Email: debl@upstate.edu